Cooperation of Harro Höfliger und LEON
Harro Höfliger and leon-nanodrugs GmbH collaborate to bring the innovative NANOus LNP-encapsulation device to market for rapid, large-scale prophylactic vaccine manufacturing.
Harro Höfliger and leon-nanodrugs GmbH ("LEON") announce today their collaboration on a manufacturing device to encapsulate mRNAs or active pharmaceutical ingredients (APIs) into lipid nanoparticles (LNPs). NANOus is a flexible small-to-high-volume manufacturing device designed for aseptic GMP-compliant nanoencapsulation of APIs, based on LEON’s proprietary NANOnow technology.
The two companies are in the process of assembling the market-ready device, which will enable rapid and cost-efficient, seamless scale-up for production of LNP-encapsulated therapeutics. NANOus can enable continuous manufacturing of several million vaccine doses per day. The collaboration builds on Harro Höfliger’s longstanding experience and engineering capabilities in order to meet the needs of the manufacturing pharmaceutical sector, while LEON provides access to its core technology platform NANOnow.